Liver stiffness assessed by Fibrosis-4 index predicts mortality in patients with heart failure

Open Heart

Volumn 4, Issue 1, 2017, Pages

  Sato, Yu ^a   Yoshihisa, Akiomi ^a   Kanno, Yuki ^a   Watanabe, Shunsuke ^a   Yokokawa, Tetsuro ^a   Abe, Satoshi ^a   Misaka, Tomofumi ^a   Sato, Takamasa ^a   Suzuki, Satoshi ^a   Oikawa, Masayoshi ^a   Kobayashi, Atsushi ^a   Yamaki, Takayoshi ^a   Kunii, Hiroyuki ^a   Nakazato, Kazuhiko ^a   Saitoh, Shu Ichi ^a   Takeishi, Yasuchika ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

heart failure

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; COLLAGEN TYPE 4; COLLAGEN TYPE 4 7S; HYALURONIC ACID; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; FIBROSIS 4 INDEX; FOLLOW UP; HEART FAILURE; HEART FUNCTION; HEART LEFT ATRIUM; HEART RIGHT ATRIUM; HUMAN; INFERIOR CAVA VEIN; LIVER FIBROSIS; LIVER STIFFNESS; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; THROMBOCYTE COUNT;

EID: 85019028813     PISSN: None     EISSN: 20533624     Source Type: Journal    
DOI: 10.1136/openhrt-2017-000598     Document Type: Article

References (30)

1. Ponikowski P, Voors AA, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the heart failure association (HFA) of the ESC. Eur J Heart Fail 2016; 2016: 891-975.
2. Samsky MD, Patel CB, DeWald TA, et al. Cardiohepatic interactions in heart failure: an overview and clinical implications. J Am Coll Cardiol 2013; 61: 2397-405.
3. Møller S, Bernardi M. Interactions of the heart and the liver. Eur Heart J 2013; 34: 2804-11.
4. Nikolaou M, Parissis J, Yilmaz MB, et al. Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure. Eur Heart J 2013; 34: 742-9.
5. Jalal Z, Iriart X, De Lédinghen V, et al. Liver stiffness measurements for evaluation of central venous pressure in congenital heart diseases. Heart 2015; 101: 1499-504.
6. Taniguchi T, Sakata Y, Ohtani T, et al. Usefulness of transient elastography for noninvasive and reliable estimation of right-sided filling pressure in heart failure. Am J Cardiol 2014; 113: 552-8.
7. Colli A, Pozzoni P, Berzuini A, et al. Decompensated chronic heart failure: increased liver stiffness measured by means of transient elastography. Radiology 2010; 257: 872-8.
8. Shah AG, Lydecker A, Murray K, et al. Nash Clinical Research Network. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7: 1104-12.
9. Sanyal AJ. American Gastroenterological A. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1705-25.
10. Grigorescu M. Noninvasive biochemical markers of liver fibrosis. J Gastrointestin Liver Dis 2006; 15: 149-59.
11. McKee PA, Castelli WP, McNamara PM, et al. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971; 285: 1441-6.
12. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-54.
13. von Elm E, Altman DG, Egger M, et al. Strengthening the Reporting of Observational studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007; 335: 806-8.
14. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006; 7: 79-108.
15. Kalra PR, Anagnostopoulos C, Bolger AP, et al. The regulation and measurement of plasma volume in heart failure. J Am Coll Cardiol 2002; 39: 1901-8.
16. Mohamed BA, Schnelle M, Khadjeh S, et al. Molecular and structural transition mechanisms in long-Term volume overload. Eur J Heart Fail 2016; 18: 362-71.
17. Mullens W, Abrahams Z, Francis GS, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009; 53: 589-96.
18. Testani JM, Chen J, McCauley BD, et al. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation 2010; 122: 265-72.
19. Millonig G, Friedrich S, Adolf S, et al. Liver stiffness is directly influenced by central venous pressure. J Hepatol 2010; 52: 206-10.
20. Yoshitani T, Asakawa N, Sakakibara M, et al. Value of virtual touch quantification elastography for assessing liver congestion in patients with heart failure. Circ J 2016; 80: 1187-95.
21. Birrer R, Takuda Y, Takara T. Hypoxic hepatopathy: pathophysiology and prognosis. Intern Med 2007; 46: 1063-70.
22. Kamimoto Y, Horiuchi S, Tanase S, et al. Plasma clearance of intravenously injected aspartate aminotransferase isozymes: evidence for preferential uptake by sinusoidal liver cells. Hepatology 1985; 5: 367-75.
23. Cogger VC, Fraser R, Le Couteur DG. Liver dysfunction and heart failure. Am J Cardiol 2003; 91: 1399.
24. Fotbolcu H, Zorlu E. Nonalcoholic fatty liver disease as a multi-systemic disease. World J Gastroenterol 2016; 22: 4079-90.
25. Brea A, Puzo J. Non-Alcoholic fatty liver disease and cardiovascular risk. Int J Cardiol 2013; 167: 1109-17.
26. Targher G, Bertolini L, Padovani R, et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 2006; 29: 1325-30.
27. Brea A, Mosquera D, Martín E, et al. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol 2005; 25: 1045-50.
28. Yilmaz Y, Kurt R, Yonal O, et al. Coronary flow reserve is impaired in patients with nonalcoholic fatty liver disease: association with liver fibrosis. Atherosclerosis 2010; 211: 182-6.
29. Bhatia LS, Curzen NP, Calder PC, et al. Non-Alcoholic fatty liver disease: a new and important cardiovascular risk factor?. Eur Heart J 2012; 33: 1190-200.
30. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341-50.